Janssen’s Tremfya shows promise in two Phase III psoriatic arthritis trials
Johnson & Johnson subsidiary Janssen has announced that Tremfya (guselkumab) reached its primary...
Focus:
Most Read
Latest Content
Terns to commercialise GENFIT’s elafibranor to treat NASH and PBC
Terns Pharmaceuticals has signed an agreement to acquire the exclusive rights to develop, register and market GENFIT’s elafibranor.
Janssen’s Tremfya shows promise in two Phase III psoriatic arthritis trials
Johnson & Johnson subsidiary Janssen has announced that Tremfya (guselkumab) reached its primary endpoint in the Phase III DISCOVER one and two studies, where it is being investigated for adults with moderate to severe psoriatic arthritis.
Diabetes Week: investigating the immune basis of type 1 diabetes
Diabetes UK use its annual Diabetes Week to raise awareness, as well as funds for, among other things, crucial research into new treatments for diabetes. One largely neglected therapeutic approach the charity has invested in is repurposing immunotherapies from other autoimmune diseases for type 1 diabetes, linked with the immune system’s role in destroying pancreatic cells.
Latest News
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.
Close
Close
Close
Go Top
